, Hong Kong
434 views
AstraZeneca

AstraZeneca unveils new R&D centre in Hong Kong

The R&D centre will focus on cell and gene therapy studies.

UK-based biopharmaceutical company AstraZeneca has launched a research and development (R&D) centre in Hong Kong.

The R&D centre in Hong Kong will focus on research and development of medicines in cell and gene therapy.

AstraZeneca also launched the Hong Kong iCampus, which will assist startups to broaden the medical innovation ecosystem.

AstraZeneca also organised a group of 80 Mainland pharmaceutical and biotechnology enterprises to visit Hong Kong. 

Join Hong Kong Business community

The group comprises large-scale listed enterprises and startups engaging in pioneering pharmaceutical technologies.

Follow the link for more news on

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

Commercial floors at 382 Lockhart Road up for sale
The indicative price is set at $398M, or approximately $8,405 per square foot.
Hong Kong logistics rental softens in H1
Tenants’ adjustment and tariff risks dragged rental prices and activities.
HKMA fines three banks for violating anti-money laundering policies
HKMA ordered fines and formulation of remedial measures.The Hong Kong Monetary Authority (HKMA) has conducted disciplinary action against Indian Overseas Bank, Hong Kong Branch (IOBHK), Bank of Communications (Hong Kong) Limited (BCOM(HK)), and Bank of Communications Co., Ltd., Hong Kong Branch (BCOM) for violating the Anti-Money Laundering and Counter-Terrorist Financing Ordinance (Chapter 615 of the Laws of Hong Kong) (AMLO) on 22 July.